Please note, this OEL/ADE monograph also applies to brimonidine tartrate (CAS RN 70359-46-5). Brimonidine is indicated for the treatment of ocular high blood pressure, open-angle glaucoma and rosacea on the face. Brimonidine tartrate, a relatively selective alpha-2 adrenergic agonist, is used ophthalmically to lower intraocular pressure in open-angle glaucoma or ocular high blood pressure by reducing aqueous humor production and increasing eye-related fluid outflow. Applied as a topical gel to the facial area, brimonidine tartrate may decrease redness via direct vasoconstriction.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Brimonidine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.